ArticleJournal of applied statistics2026
Optimizing personalized screening intervals for clinical biomarkers using extended joint models.
Article in Journal of applied statistics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Redefining cardiometabolic biomarkers in the big data era: toward a personalized medicine-centered reconstruction of risk prediction models.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research advances joint modeling and personalized scheduling for HIV and TB by incorporating censored longitudinal outcomes in multivariate joint models, providing a more flexible and accurate approach for complex data scenarios. Inspired by the SAPiT study, we deviate from standard model selection procedures by using super learning techniques to identify the optimal model for predicting future events in event-free subjects. Specifically, the Integrated Brier score and Expected Predictive Cross-Entropy (EPCE) identified the multivariate joint model with the parameterization of the area under the longitudinal profiles of CD4 count and viral load as optimal and strong predictors of death. Integrating this model with a risk-based screening strategy, we recommend extending intervals to 10.3 months for stable patients, with additional measurements every 12 months. For patients with deteriorating health, we suggest a 3.5-month interval, followed by 6.2 months, and then annual screenings. These findings refine patient care protocols and advance personalized medicine in HIV/TB co-infected individuals. Furthermore, our approach is adaptable, allowing adjustments based on patients' evolving health status. While focused on HIV/TB co-infection, this method has broader applicability, offering a promising avenue for biomarker studies across various disease populations and potential for future clinical trials and biomarker-guided therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.